Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?
作者信息
Lunning Matthew A, Armitage James O
机构信息
University of Nebraska Medical Center, Internal Medicine Department, Hematology/Oncology Division, Omaha, NE, USA.
University of Nebraska Medical Center, Internal Medicine Department, Hematology/Oncology Division, Omaha, NE, USA
出版信息
Haematologica. 2015 Jul;100(7):853-5. doi: 10.3324/haematol.2015.129924.
Abstract
摘要
相似文献
1
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?
Haematologica. 2015 Jul;100(7):853-5. doi: 10.3324/haematol.2015.129924.
2
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
3
[Richter syndrome: report of a case].
Zhonghua Bing Li Xue Za Zhi. 2010 Jul;39(7):487-8.
4
Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.
5
Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma.
Minerva Med. 2021 Apr;112(2):310-312. doi: 10.23736/S0026-4806.19.06236-0. Epub 2019 Jul 17.
6
Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Blood. 2004 Sep 1;104(5):1584-5; author reply 1585-6. doi: 10.1182/blood-2004-04-1266.
7
[Primary diffuse large B-cell lymphoma in uterine corpus: report of a case].
Zhonghua Bing Li Xue Za Zhi. 2011 Apr;40(4):270-2.
8
Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):8-9.
9
Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Eur J Haematol. 2015 Jun;94(6):504-10. doi: 10.1111/ejh.12459. Epub 2014 Nov 21.
10
CHOP plus rituximab--balancing facts and opinion.
N Engl J Med. 2002 Jan 24;346(4):280-2. doi: 10.1056/NEJM200201243460411.
引用本文的文献
1
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.
Rheumatology (Oxford). 2018 Apr 1;57(4):639-650. doi: 10.1093/rheumatology/kex484.
本文引用的文献
1
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.
Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.
2
Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):8-9.
3
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
J Clin Oncol. 2014 Dec 20;32(36):4127-33. doi: 10.1200/JCO.2013.54.6861. Epub 2014 Nov 17.
4
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4.
5
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
J Clin Oncol. 2013 Sep 20;31(27):3351-9. doi: 10.1200/JCO.2012.44.8290. Epub 2013 Aug 19.
6
Treatment of older patients with mantle-cell lymphoma.
N Engl J Med. 2012 Aug 9;367(6):520-31. doi: 10.1056/NEJMoa1200920.
7
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Blood. 2012 Apr 5;119(14):3276-84. doi: 10.1182/blood-2011-09-380949. Epub 2012 Feb 15.
8
How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.
J Cancer Res Clin Oncol. 2012 Jan;138(1):125-32. doi: 10.1007/s00432-011-1074-1. Epub 2011 Nov 6.
9
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
10
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2.
Zotero 插件